TEVA
Teva Pharmaceutical·NYSE
--
--(--)
--
--(--)
6.07 / 10
Outperform
Analyst coverage is overwhelmingly positive (Strong Buy 66.7%, Buy 33.3%) with high historical win rates, indicating strong conviction. Fund-flow data show robust overall and block inflows (positive trends) but smaller outflows in the Medium and Small categories. The fund-flow score of 7.74/10 is good, aligning with the bullish analyst view. Together, the analyst and funding sides reinforce a cautiously optimistic tone, though not enough to override the fundamental and technical concerns.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
67%
Buy
33%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-30
InstitutionBarclays
Times predicted3
Historical Win Rate100.0%
What is the analyst consensus for TEVA?
- TEVA holds a Bearish analyst rating, with 67% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.07/10 (Outperform).
